1. Academic Validation
  2. DP-b99 modulates matrix metalloproteinase activity and neuronal plasticity

DP-b99 modulates matrix metalloproteinase activity and neuronal plasticity

  • PLoS One. 2014 Jun 11;9(6):e99789. doi: 10.1371/journal.pone.0099789.
Marine Yeghiazaryan 1 Izabela Rutkowska-Wlodarczyk 2 Anna Konopka 1 Grzegorz M Wilczyński 1 Armenuhi Melikyan 3 Eduard Korkotian 4 Leszek Kaczmarek 2 Izabela Figiel 2
Affiliations

Affiliations

  • 1 Department of Neurophysiology, The Nencki Institute of Experimental Biology, Warsaw, Poland.
  • 2 Department of Molecular and Cellular Neurobiology, The Nencki Institute of Experimental Biology, Warsaw, Poland.
  • 3 D-Pharm Ltd, Kiryat Weizmann Science Park, Rehovot, Israel.
  • 4 Department of Neurobiology, Weizmann Institute, Rehovot, Israel.
Abstract

DP-b99 is a membrane-activated chelator of zinc and calcium ions, recently proposed as a therapeutic agent. Matrix Metalloproteinases (MMPs) are zinc-dependent extracellularly operating proteases that might contribute to synaptic plasticity, learning and memory under physiological conditions. In excessive amounts these Enzymes contribute to a number of neuronal pathologies ranging from the stroke to neurodegeneration and epileptogenesis. In the present study, we report that DP-b99 delays onset and severity of PTZ-induced seizures in mice, as well as displays neuroprotective effect on kainate excitotoxicity in hippocampal organotypic slices and furthermore blocks morphological reorganization of the dendritic spines evoked by a major neuronal MMP, MMP-9. Taken together, our findings suggest that DP-b99 may inhibit neuronal plasticity driven by MMPs, in particular MMP-9, and thus may be considered as a therapeutic agent under conditions of aberrant plasticity, such as those subserving epileptogenesis.

Figures
Products